Lbp Am Sa Buys 15,652 Shares of Becton, Dickinson and Company (NYSE:BDX)

LBP AM SA increased its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 4.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 342,485 shares of the medical instruments supplier's stock after acquiring an additional 15,652 shares during the period. Becton, Dickinson and Company comprises about 1.2% of LBP AM SA's holdings, making the stock its 16th largest holding. LBP AM SA owned approximately 0.12% of Becton, Dickinson and Company worth $78,450,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $27,000. REAP Financial Group LLC increased its position in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares during the last quarter. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $29,000. Cornerstone Planning Group LLC increased its position in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 99 shares during the last quarter. Finally, Picton Mahoney Asset Management increased its position in Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 54 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

BDX traded down $1.63 during midday trading on Friday, reaching $175.87. The company's stock had a trading volume of 2,428,716 shares, compared to its average volume of 2,077,671. The stock has a market cap of $50.41 billion, a P/E ratio of 33.56, a PEG ratio of 1.33 and a beta of 0.25. The company has a fifty day simple moving average of $172.33 and a 200 day simple moving average of $205.91. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the firm posted $3.17 EPS. The company's revenue was up 4.5% on a year-over-year basis. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were given a $1.04 dividend. The ex-dividend date of this dividend was Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.37%. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.

Analyst Ratings Changes

A number of brokerages have recently commented on BDX. Piper Sandler lowered Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and lowered their price objective for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Morgan Stanley lowered their price objective on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. The Goldman Sachs Group lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective on the stock. in a report on Friday, May 2nd. Wall Street Zen lowered Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Finally, Wells Fargo & Company lowered Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $219.22.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president owned 4,575 shares in the company, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.36% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.